Page Menu

Cancer Physiology Department Metrics

View the clinical trials, grants and publications from the Department of Cancer Physiology.

Clinical Trials
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 3 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Chemoembolization of Neuroendocrine Liver Metastases
Condition: Gastrointestinal Tumor
Intervention: Adriamycin (doxorubicin); Not Applicable (); doxorubicin ()

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Condition: Gastrointestinal Tumor
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Xeloda (capecitabine); capecitabine (); gemcitabine ()

A Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms
Condition: Genitourinary

A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Condition: Gastrointestinal Tumor
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Not Applicable (); Yttrium-90 ()

  • Radiomics of NSCLC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Schabath, M.
  • Year 3 of DOS47 (Cecam6-Targeted Urease) in Combination with Checkpoint Blockade
    Sponsor: Helix Biopharma Corp
    PI:Gillies, R.,CO-PI:Ibrahim Hashim, A.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Investigation of NRF2-Dependent Metabolic Liabilities
    Sponsor: Nat Institutes of Health
    PI:DeNicola, G.
  • Perturbing the Evolutionary Drivers of Targeted Therapy Resistance in NSCLC
    Sponsor: Amer Cancer Society
    PI:Marusyk, A.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
  • Therapeutic strategies for KEAP1/NRF2 mutant lung cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.
  • Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
    Sponsor: Nat Institutes of Health
    PI:Marusyk, A.
  • Disrupting Resistance to Targeted Therapies in NSCLC with Evolutionary Informed Therapies
    Sponsor: US Army
    PI:Marusyk, A.
  • Impact of Stromal Architecture on the Response of Lung Cancers to Targeted Therapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Marusyk, A.,CO-PI:Altrock, P.,CO-PI:Basanta Gutierrez, D.
  • Metabolic basis of the NADPH-independent disulfide reductase system in mouse liver
    Sponsor: Nat Institutes of Health
    PI (MPI):DeNicola, G.
  • Disrupting Microenvironment-Mediated Tumor Repopulation Dynamics During Therapy to Improve Cure Rates in Triple Negative Breast Cancer
    Sponsor: Florida Breast Cancer Foundation
    PI:Marusyk, A.,CO-PI:Basanta Gutierrez, D.
  • Promoting healthy adipocyte function: a novel therapeutic strategy to uncouple obesity from metabolic disease and co-morbidities
    Sponsor: Moffitt Cancer Center
    PI:McDonald, P.
  • Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Effects of novel glucagon-like peptide 1 receptor (GLP-1R) agonists on comorbidities in Alzheimer's disease with diabetes mellitus.
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:McDonald, P.
  • Pyridine Nucleotides: Missing Link between Aging and Lung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:DeNicola, G.,CO-PI:Gomes, A.
  • Evolution of Evolability Under Targeted Therapies
    Sponsor: Moffitt Cancer Center
    PI:Marusyk, A.
  • Predicting Dose Maps Adaptive Sterotatic Radiotherapy of Breast Cancer Metastases of the Brain St of FL COE Pilot Project 2
    Sponsor: Moffitt Cancer Center
    PI:Raghunand, N.,CO-PI:Ahmed, K.
  • Conjugates for Detection of Breast Cancer Nodal Metastasis
    Sponsor: Moffitt Cancer Center
    PI:Morse, D.,CO-PI:Luca, V.
  • Defining and targeting the pro-tumorigenic metabolic microenvironment of leptomeningeal metastasis in triple-negative breast cancer
    Sponsor: Florida Breast Cancer Foundation
    PI (Contact):Smalley, I.
  • Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
    Sponsor: US Army
    PI:Morse, D.
  • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Smalley, I.
  • Tumor-Stroma Metabolic Crosstalk in Melanoma Brain Metastases
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.,CO-PI:Chen, A.
  • "Developing spatial multi-omics approaches for the study of the tumor microenvironment"
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.
  • Tumor-stroma metabolic crosstalk in melanoma brain metastases
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Smalley, I.
  • Ecology and Evolution of Breast Carcinogenesis
    Sponsor: Nat Institutes of Health
    PI:Silva, A.
  • Vander Velde R, Shaffer S, Marusyk A. Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. Trends Cancer. 2022 Jun.8(6):456-466. Pubmedid: 35307314.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
  • Li J, DeNicola GM, Ruffell B. Metabolism in tumor-associated macrophages. Int Rev Cell Mol Biol. 2022 Apr.367:65-100. Pubmedid: 35461660. Pmcid: PMC9094395.
  • Foo J, Basanta D, Rockne RC, Strelez C, Shah C, Ghaffarian K, Mumenthaler SM, Mitchell K, Lathia JD, Frankhouser D, Branciamore S, Kuo YH, Marcucci G, Vander Velde R, Marusyk A, Hang S, Hari K, Jolly MK, Hatzikirou H, Poels K, Spilker M, Shtylla B, Robertson-Tessi M, Anderson ARA. Roadmap on plasticity and epigenetics in cancer. Phys Biol. 2022 Apr.19(3). Pubmedid: 35078159.
  • Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther. 2022 Mar. Pubmedid: 35332245.
  • Ospina OE, Wilson CM, Soupir AC, Berglund A, Smalley I, Tsai KY, Fridley B. spatialGE: Quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics. 2022 Mar. Pubmedid: 35258565.
  • Tomaszewski MR, Fan S, Garcia A, Qi J, Kim Y, Gatenby RA, Schabath MB, Tap WD, Reinke DK, Makanji RJ, Reed DR, Gillies RJ. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance. Tomography. 2022 Feb.8(1):341-355. Pubmedid: 35202193. Pmcid: PMC8880510.
  • Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LT, Van Aelst L, Xi D, Yuan P, Brady DC, Chang CJ. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022 Feb.22(2):102-113. Pubmedid: 34764459. Pmcid: PMC8810673.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Feb. Pubmedid: 35213727.
  • Bailey T, Nieto A, McDonald P. Inhibition of the Monocarboxylate Transporter 1 (MCT1) Promotes 3T3-L1 Adipocyte Proliferation and Enhances Insulin Sensitivity. Int J Mol Sci. 2022 Feb.23(3). Pubmedid: 35163825. Pmcid: PMC8836706.
  • Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone PAS. Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy. Can J Urol. 2022 Feb.29(1):10976-10978. Pubmedid: 35150217.
  • Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2022 Feb.22(2):e214-e223. Pubmedid: 34384695.
  • Gillies RJ. Cancer heterogeneity and metastasis: life at the edge. Clin Exp Metastas. 2022 Feb.39(1):15-19. Pubmedid: 33999364.
  • Bayer P, Gatenby RA, McDonald PH, Duckett DR, Staňková K, Brown JS. Coordination games in cancer. PLoS One. 2022 Jan.17(1):e0261578. Pubmedid: 35061724. Pmcid: PMC8782377.
  • Torrente L, DeNicola GM. Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges. Annu Rev Pharmacol Toxicol. 2022 Jan.62:279-300. Pubmedid: 34499527.
  • Nieto A, Bailey T, Kaczanowska K, McDonald P. GABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators. Curr Top Behav Neurosci. 2022.52:81-118. Pubmedid: 34036555.
  • Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiat Oncol. 2021 Dec.16(1):237. Pubmedid: 34911546. Pmcid: PMC8672552.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Kammer MN, Lakhani DA, Balar AB, Antic SL, Kussrow AK, Webster RL, Mahapatra S, Barad U, Shah C, Atwater T, Diergaarde B, Qian J, Kaizer A, New M, Hirsch E, Feser WJ, Strong J, Rioth M, Miller Y, Balagurunathan Y, Rowe DJ, Helmey S, Chen SC, Bauza J, Deppen SA, Sandler K, Maldonado F, Spira A, Billatos E, Schabath MB, Gillies RJ, Wilson DO, Walker RC, Landman B, Chen H, Grogan EL, Barón AE, Bornhop DJ, Massion PP. Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules. Am J Respir Crit Care Med. 2021 Dec.204(11):1306-1316. Pubmedid: 34464235. Pmcid: PMC8786067.
  • Pandey S, Snider AD, Moreno WA, Ravi H, Bilgin A, Raghunand N. Joint total variation-based reconstruction of multiparametric magnetic resonance images for mapping tissue types. Nmr Biomed. 2021 Dec.34(12):e4597. Pubmedid: 34390047.
  • Ji K, Zhao Z, Sameni M, Moin K, Xu Y, Gillies RJ, Sloane BF, Mattingly RR. Modeling Tumor: Lymphatic Interactions in Lymphatic Metastasis of Triple Negative Breast Cancer. Cancers (Basel). 2021 Nov.13(23). Pubmedid: 34885152. Pmcid: PMC8656640.
  • Yoon SJ, DeNicola GM. IL1RAP Pulls a Double Shift in the Cysteine Factory. Cancer Discov. 2021 Nov.11(11):2679-2681. Pubmedid: 34725089.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
  • DeNicola GM, Shackelford DB. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. Cold Spring Harb Perspect Med. 2021 Nov.11(11). Pubmedid: 34127512. Pmcid: PMC8559540.
  • Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, Li L, Sharma K, Nkwocha J, Parker R, Bui D, McCarter J, Kramer L, Purcell C, Sudalagunta P, Renatino Canevarolo R, Coelho Siqueira Silva MD, DeAvila G, Alugubelli RR, Siqueira Silva A, Kmieciak M, Ferreira-Gonzalez A, Shain KH, Grant S. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms. Blood Adv. 2021 Oct.5(19):3776-3788. Pubmedid: 34464977. Pmcid: PMC8679669.
  • Pfaehler E, Zhovannik I, Wei L, Boellaard R, Dekker A, Monshouwer R, El Naqa I, Bussink J, Gillies R, Wee L, Traverso A. A systematic review and quality of reporting checklist for repeatability and reproducibility of radiomic features. Phys Imaging Radiat Oncol. 2021 Oct.20:69-75. Pubmedid: 34816024. Pmcid: PMC8591412.
  • Maccioni P, Kaczanowska K, Lawrence H, Yun S, Bratzu J, Gessa GL, McDonald P, Colombo G. The Novel Positive Allosteric Modulator of the GABAB Receptor, KK-92A, Suppresses Alcohol Self-Administration and Cue-Induced Reinstatement of Alcohol Seeking in Rats. Front Cell Dev Biol. 2021 Oct.9:727576. Pubmedid: 34778249. Pmcid: PMC8585307.
  • Lin S, Li Y, Wang D, Huang C, Marino D, Bollt O, Wu C, Taylor MD, Li W, DeNicola GM, Hao J, Singh PK, Yang S. Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. Cancer Lett. 2021 Oct.518:230-242. Pubmedid: 34303764. Pmcid: PMC8355190.
  • Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021 Oct.48(11):3408-3421. Pubmedid: 33772332.
  • Tunali I, Tan Y, Gray JE, Katsoulakis E, Eschrich SA, Saller J, Aerts HJWL, Boyle T, Qi J, Guvenis A, Gillies RJ, Schabath MB. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectr. 2021 Aug.5(4). Pubmedid: 34409252. Pmcid: PMC8363765.
  • Tunali I, Gillies RJ, Schabath MB. Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine. Cold Spring Harb Perspect Med. 2021 Aug.11(8). Pubmedid: 33431509. Pmcid: PMC8288444.
  • Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum J, Clarke BN, Coleman N, Dewaraja YK, Frey EC, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos C, Larson SM, Lin FI, Madsen MT, Mirzadeh S, Morse DL, Pryma DA, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico PB, Zukotynski KB. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2021 Aug.62(8):1133-1139. Pubmedid: 33277396. Pmcid: PMC8833877.
  • Kingsley JL, Costello JR, Raghunand N, Rejniak KA. Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations. PLoS Comput Biol. 2021 Jul.17(7):e1009206. Pubmedid: 34310608. Pmcid: PMC8341701.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
  • Mu W, Katsoulakis E, Whelan CJ, Gage KL, Schabath MB, Gillies RJ. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Brit J Cancer. 2021 Jul.125(2):229-239. Pubmedid: 33828255. Pmcid: PMC8292339.
  • González-Sánchez P, DeNicola GM. The microbiome(s) and cancer: know thy neighbor(s). J Pathol. 2021 Jul.254(4):332-343. Pubmedid: 33723873.
  • Niell BL, Abdalah M, Stringfield O, Raghunand N, Ataya D, Gillies R, Balagurunathan Y. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk. Ajr Am J Roentgenol. 2021 Jul.217(1):64-75. Pubmedid: 32876474.
  • Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, Tian J, Gillies RJ, Schabath MB. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135101. Pmcid: PMC8211060.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
  • Messan MR, Damaghi M, Freischel A, Miao Y, Brown J, Gillies R, Wallace D. Predicting the results of competition between two breast cancer lines grown in 3-D spheroid culture. Math Biosci. 2021 Jun.336:108575. Pubmedid: 33757835.